Tumor Infiltrating Lymphocytes Adjuvant Therapy of Melanoma

Inclusion Criteria:

* Melanoma stage III (regional lymph node recurrence). Will be selected the patients with only one invaded lymph node confirmed by anatomopathological exam after lymph nodes excision.
* Absence of visceral metastases verified by physical examination, chest radiography, liver echography and brain-chest-liver CT-Scan.
* Age \< 75 years, both genders
* ECOG 0-2, Karnofsky \> 80%.
* Negative pregnancy test performed at the screening visit for fertile women.
* The potentially fertile women must use an oral contraception or an intra-uterine device (IUD) until three months following the last injection of the study treatment.
* The patients must have fully recovered from surgery.
* HIV 1/2: The patients must be negative for antibodies HIV 1 and HIV 2 and for Ag P24 or DGV HIV.
* HBV: The patients must be negative for the antigen, but can be positive for the antibodies but with a negative DNA PCR.
* HCV: The patients must be negative for the antibodies.
* HTLV ½: The patients must be negative for the antibodies.
* Following laboratory results:

  * Hemoglobin: ≥ 10 g/dl
  * WBC: ≥ 4000/µl
  * Lymphocytes: ≥ 700/µl
  * Platelet count: ≥ 100.000/µl
  * Serum creatinine: \< 2.0 mg/dl or £ 177 mmol/l
  * Serum Bilirubin: \< 2.0 mg/dl or £ 34.2 mmol/l
  * ASAT and ALAT: \< 2.5 x the upper limit of normal.

Exclusion criteria:

* Patient with more than one invaded lymph node confirmed by anatomopathological exam.
* Presence of melanoma metastases discovered by clinical or radiological examination at the screening visit.
* Patients must not have received any Chemotherapy, immunotherapy or radiotherapy within the preceding 4 weeks (6 weeks since prior nitrosurea and mitomycin C therapies).
* Presence of cardiac affections (congestive cardiac insufficiency, coronaropathy, not controlled HTA).
* Any serious active medical illnesses, for example: Active systemic infections requiring of antibiotics, coagulation disorders or any other condition which requires concomitant medications not allowed during this study.
* Presence of the second active cancer other than surgically cured non-melanoma skin cancer or cervical carcinoma in-situ.
* Any affection requiring a systemic corticotherapy or a treatment by Interferon A.
* Any active auto-immune disease including the insulin-dependent diabetes or a immunodeficiency. The vitiligo is not an exclusion criteria.
* Thyroid dysfunction not responsive to therapy.
* Positive Serology for HIV, HVB, HVC or HTLV1/2.
* Woman pregnant or nursing or without an effective contraception.
* Incapacity to give written consent.